Pages that link to "Q28247684"
Jump to navigation
Jump to search
The following pages link to Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B (Q28247684):
Displaying 50 items.
- Novel non-viral method for transfection of primary leukemia cells and cell lines (Q24794695) (← links)
- Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia (Q26744283) (← links)
- An update of current treatments for adult acute myeloid leukemia (Q26776396) (← links)
- Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients (Q26799609) (← links)
- Post-remission therapy for acute myeloid leukemia (Q26995867) (← links)
- Progress in acute myeloid leukemia (Q27024006) (← links)
- Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia (Q27851713) (← links)
- Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia (Q28191301) (← links)
- (Q29037336) (redirect page) (← links)
- Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission (Q30408294) (← links)
- Myelodysplasia nd the leukemias (Q30428471) (← links)
- Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data (Q30711100) (← links)
- Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation (Q30941745) (← links)
- High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission (Q31416964) (← links)
- A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...] (Q31893384) (← links)
- Therapy of acute myeloid leukemia (Q31929964) (← links)
- Systems of protocol review, quality assurance, and data audit (Q32016096) (← links)
- Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group (Q32083078) (← links)
- Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF. (Q32118858) (← links)
- High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. (Q33259951) (← links)
- Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen (Q33332473) (← links)
- Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study (Q33357735) (← links)
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (Q33380148) (← links)
- Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). (Q33401383) (← links)
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia (Q33412609) (← links)
- Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia (Q33415379) (← links)
- Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia (Q33417145) (← links)
- A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. (Q33423753) (← links)
- Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. (Q33434223) (← links)
- Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia (Q33499399) (← links)
- Thrombopoietic factors potentially useful in the treatment of acute leukemia (Q33505050) (← links)
- Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy (Q33515031) (← links)
- A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia (Q33630851) (← links)
- Acute myeloid leukemia in the elderly: 'per aspera ad astra'? (Q33684133) (← links)
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy (Q33717707) (← links)
- Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia. (Q33734101) (← links)
- Management of relapsed acute myeloid leukaemia (Q33751243) (← links)
- Autologous bone marrow transplantation in acute leukemia (Q33769677) (← links)
- Acute myelogenous leukemia and aging. Clinical interactions (Q33841179) (← links)
- Relapsed acute myeloid leukemia: why is there no standard of care? (Q33877202) (← links)
- SAMHD1 protects cancer cells from various nucleoside-based antimetabolites (Q33878949) (← links)
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (Q33897586) (← links)
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (Q33949752) (← links)
- Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation (Q33968321) (← links)
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (Q33990856) (← links)
- Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years (Q33999115) (← links)
- Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (Q34052614) (← links)
- Transcription therapy for acute promyelocytic leukaemia (Q34074712) (← links)
- Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology (Q34099411) (← links)
- Therapy for acute myeloid leukemia: intensive timing of induction chemotherapy (Q34108102) (← links)